Malignant transformation of the esophageal mucosa is enhanced in p27 knockout mice  by Ellis, F.Henry et al.
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 4 809
TX
ET
G
TS
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
Ellis et al General Thoracic Surgery
Objective: In a previous study, we showed that experimentally induced gastroduo-
denal-esophageal reflux in mice treated with a carcinogen can result in Barrett
esophagus and Barrett-associated adenocarcinoma. Since we have shown that most
Barrett-associated adenocarcinomas in human beings have lost the tumor suppres-
sor gene p27, we sought to determine whether cancer would be more likely to devel-
op in p27 knockout mice than in p27 heterozygous or p27 wild type mice.
Methods: Three groups of mice were treated by esophagojejunostomy resulting in
gastroduodenal-esophageal reflux and by a carcinogen (N-methyl-N-benzylni-
trosamine): group I (50 wild type), group II (45 p27 heterozygous), and group III
(50 p27 knockout). The mice were killed 18 to 20 weeks after operation and stud-
ied macroscopically and histopathologically.
Results: Barrett esophagus developed in 7 (14%) mice in group I, 4 (8.9%) mice in
group II, and 13 (26%) mice in group III. Cancers developed in 30 (60%) mice in
group I, 31 (68%) mice in group II, and 43 (86%) mice in group III. Ten percent of
the cancers in group I were adenocarcinomas, as were 16.1% in group II, and 23.3%
in group III. The difference between rates of Barrett esophagus in groups I and II
compared with group III was statistically significant (P = .035), as was true of the
cancer rates (P = .006). The percentage of cancers that were adenocarcinomas was
highest in group III, but not significantly different from groups I and II.
Conclusions: This experimental mouse model of Barrett esophagus and Barrett-
associated adenocarcinoma is similar to what occurs in human beings and may be use-
ful in developing methods to inhibit malignant transformation of Barrett esophagus.
The rising prevalence of adenocarcinoma of the esophagus in theWestern world is a widely recognized fact.1-3 The development ofmetaplastic columnar epithelium of the esophagus, or Barrett esopha-gus (BE), is thought to be the result of reflux of acid and alkalinesecretions into the esophagus. This metaplastic epithelium is suscepti-ble to malignant transformation resulting in Barrett-associated adeno-
carcinoma (BAA). An additional source of this metaplastic epithelium may be from
short tongues of intestinal-type epithelium in the region of the cardia, leading to the
suggestion by Cameron and associates4 that 21% to 79% of cancers classified as can-
cers of the cardia may actually originate from short segments of Barrett epithelium.
The cyclin-dependent kinase inhibitor p27 acts as a negative regulator of the cell
division cycle, regulating progression from the G1 to the S phase of the cell cycle. In
a study of 58 resected specimens of BAA, using immunohistochemistry and in situ
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hybridization, we found that loss of p27 expression occurred
in most cases of BAA and was associated with a poor prog-
nosis,5 as is the case in a variety of other tumors.6 Low p27
expression also correlated with metastases to the lymph
nodes, depth of tumor invasion, and decreased survival.
Recently, BE and BAA have been produced experimen-
tally in the rat by various surgical maneuvers designed to
promote gastroduodenal-esophageal reflux.7,8 The availabil-
ity of transgenic and knockout technology for manipulating
gene function in the mouse model9 led us to attempt to
duplicate in the mouse the results obtained in the rat model.
We found that gastroduodenal-esophageal reflux produced
by esophagojejunostomy plus administration of the carcino-
gen N-methyl-N-benzylnitrosamine (MBN; Ash-Stevens,
Inc, Detroit, Mich) resulted in BE, BAA, or both in 57.1%
of the mice, a finding similar to that in the rat.10
The purpose of the present study was to determine
whether a genetically altered mouse lacking the p27 gene is
more susceptible to malignant transformation of the
esophageal mucosal lining than is a mouse of the wild type
with normal genetic structure.
Materials and Methods
Animals
Fifty Swiss-Webster mice with a normal genetic makeup (wild
type) obtained from Taconic Farms, Inc (Germantown, NY), were
used in this study. Two genetically altered male p27 knockout
(KO) mice were obtained from The Fred Hutchinson Cancer
Research Center, Seattle, Washington, and were used to establish a
colony of p27 KO mice by mating them with p27 wild type female
mice. From the offspring of these matings, a cohort of hybrids was
selected: 45 p27 +/– heterozygous mice and 50 p27 –/– KO mice,
the phenotypes of which were determined by polymerase chain
reaction11 performed on tail biopsy specimens.
The p27 KO mice were confirmed by polymerase chain reac-
tion amplification (94°C for 30 seconds, 56°C for 45 seconds,
72°C for 2 minutes) of the unique mutant transgene with primers:
K3: 5´-TGG AAC CCT GTG CCA TCT CTA T-3´ and N1: 5´-
CCT TCT ATG GCC TTC TTG ACG-3´, obtaining a 0.5-kilobase
(kb) band. The wild type phenotype was identified by polymerase
chain reaction amplification of a 1.0-kb band with primers K3 (see
above) and K5: 5´ GAG CAG ACG CCC AAG AAG C 3´. The het-
erozygous phenotype carried both the 1.0-kb and the 0.5-kb bands
when run on 1% agarose gel.
The animals were housed, one animal per cage, in an environ-
ment with a 12-hour light/dark cycle, at a temperature of 70°F with
a humidity of 41% ± 4%. The mice were fed commercial mouse
chow with water provided ad libitum. Solid food was withdrawn 24
hours before surgery, which was performed approximately 8 weeks
after birth. Esophagojejunostomy was performed under general
anesthesia with intraperitoneally administered sodium pentobarbi-
tal at a dose of 18.0 mg/kg. This study protocol was approved by the
Standard Committee on Animals of Harvard Medical School, and
animals were cared for according to their recommendations, which
are in compliance with the guidelines of the Institute of Laboratory
Animal Resources, National Research Council.
Surgical Procedure
The experimental procedure used was performed when the mice
were 8 weeks old and was designed to result in gastroduodenal-
esophageal reflux of gastric, bile, and pancreatic juices.12 This
intervention was accomplished through a midline abdominal inci-
sion with division of the esophagus immediately proximal to the
esophagogastric junction, which was closed with a through-and-
through suture of 6-0 polypropylene. An ellipse of anterior wall of
jejunum was excised a few millimeters distal to the ligament of
Treitz. The distal esophagus was then anastomosed to the jejunum
at the enterostomy site with 4 to 6 interrupted through-and-through
7-0 polypropylene sutures. The animals were given water 2 hours
after the operation and mouse chow the next day.
Carcinogen
MBN, a carcinogen with a predilection for inducing esophageal
cancer, was the agent used in the animals scheduled to receive car-
cinogen.13 Treatment began 1 week after the operation. The MBN
was diluted in a saline solution and given by intraperitoneal injec-
tion at a dose of 2.5 mg/kg. Injections were continued once a week
for the duration of the experiment.
Experimental Groups
The animals were divided into 3 separate groups. Group I consisted
of 50 +/+ wild type mice that underwent esophagojejunostomy plus
administration of the carcinogen. Group II consisted of 45 p27 +/–
heterozygous mice that also underwent esophagojejunostomy and
received the carcinogen, as did 50 p27 –/– KO mice in group III.
Tissue Preparation and Histopathologic Analysis
Eighteen to 20 weeks after the operation, the mice were killed with
an overdose of pentobarbital. The entire esophagus of each mouse
was removed, including the esophagojejunostomy site. The jejunum
was opened longitudinally on its mesenteric border, and the patency
of the anastomosis was determined. The esophagus was then opened
longitudinally and examined macroscopically to determine the pres-
ence or absence of esophagitis, tumor, or both. The specimen was
then photographed and prepared for histopathologic study.
Tissues were fixed in 10% formalin solution for 8 hours and
embedded longitudinally in paraffin. Next, 5-µm sections were cut
along a longitudinal axis and stained with hematoxylin and eosin.
Slides were reviewed without knowledge of treatment group
assignment. Three sections of each esophagojejunostomy speci-
men were examined. When the anastomosis was not seen, deeper
sections were obtained until the region of the anastomosis was
identified. Barrett-type mucosa was defined as intestinal-type
mucosa with goblet cell metaplasia present proximal to the anasto-
mosis and bound on both the proximal and distal ends by squa-
mous mucosa, stricter criteria than are used in human specimens.
Barrett epithelium was thus unequivocally distinguishable from
the mucosa of the small bowel (with prominent villi) to which the
esophagus was anastomosed. Presence or absence of Barrett-type
epithelium was recorded. No examples of high-grade dysplasia of
Barrett epithelium were seen. High-grade dysplasia/carcinoma in
situ of the squamous mucosa was defined by full-thickness, high-
grade squamous cell dysplasia without surface maturation, in the
absence of submucosal invasion. Invasive carcinomas were classi-
fied as squamous cell carcinomas, adenocarcinomas, or mixed
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adenosquamous carcinomas. Both high-grade dysplasia/carcinoma
in situ and invasive carcinomas were included in calculating the
cancer rate of this experimental model.
Results
All 145 mice survived the treatment schedule and were
available for study 18 to 20 weeks after the operation.
Dilatation of the distal esophagus of varying degree just
proximal to the anastomotic site was present in all speci-
mens, presumably related to moderate obstruction at the
anastomotic site (Figure 1). Macroscopic evidence suggest-
ing esophagitis consisted of redness of the mucosa, irregu-
larity of surface epithelium, or thickness of the esophageal
wall with or without ulceration (Figure 2). Some or all of
these changes were noted in 28 (56%) of the 50 mice in
group I, 35 of which have been reported on previously,10 as
well as in 13 (28.9%) mice in group II and 18 (36%) mice
in group III. Macroscopic evidence suggestive of neoplasm
was noted in 25 (50%) mice in group I, 32 (71.1%) mice in
group II, and 42 (84%) mice in group III. The tumors, for
the most part, were located at or near the site of esophago-
jejunostomy. Four mice in group III had macroscopic evi-
dence of 2 tumors. In each case, a more proximally located
lesion was found in addition to that in the vicinity of the
anastomotic site (Figure 3). No tumors were identified else-
where in the body of any mouse.
The histopathologic findings are summarized in Table 1.
Because of the similarities of results in mice of groups I and
II, these results have been combined for purposes of statisti-
cal analysis. The rates of BE and of cancer developing in this
model, not the rate of mice in which these changes developed,
was determined. BE (Figure 4, A) was identified in 7 (14%)
mice in group I (associated with cancer in 5 mice), 4 (8.9%)
mice in group II (associated with cancer in 1 mouse), and 13
(26%) mice in group III (associated with cancer in 8 mice).
None of the BE observed was associated with suture materi-
al. The rate of BE in groups I and II as compared with that of
group III was significantly different (P = .035; Fisher exact
test). Cancers were identified in 30 (60.0%) mice in group I,
31 (68.9%) mice in group II, and 43 (86%) mice in group III.
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Figure 1. Postmortem specimen from a p27 KO mouse after
esophagojejunostomy and administration of a carcinogen. Note
dilated esophagus proximal to esophagojejunostomy where a
tumor (arrow) is clearly visible.
Figure 2. Postmortem specimen from a p27 KO mouse showing
transition (arrow) from pale squamous epithelium to pink epithe-
lium of Barrett esophagus. While not visible in the gross speci-
men, islands of squamous mucosa were present at the anasto-
motic site.
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The difference in the cancer rates in groups I and II as com-
pared with that in group III was highly significant (P = 0.006;
Fisher exact test).
The number of cancers that occurred among the 3 groups
of experiments (109 cancers) exceeds that of the mice in
which they developed (104 mice) because 2 cancers devel-
oped in 5 mice, all in group III (Figure 3). Four of these
mice had an adenocarcinoma as well as a squamous cell
cancer, and another had an adenosquamous cancer as well
as a separate squamous cell cancer. Only 4 of these multiple
cancers were identifiable macroscopically, however.
Most cancers were of the squamous cell type (66 can-
cers) and predominated in the mice of group III (31 cancers)
(Figure 4, B), but 18 cancers were adenocarcinomas (Figure
4, C) and 25 cancers were adenosquamous cancers (Figure
4, D). Adenocarcinomas accounted for 10% of the cancers
in group I, 16.1% in group II, and 23.3% in group III.
Although the difference in the rates between groups I and II
compared with group III (13.1% compared with 23.3%) was
not significant, the trend is highly suggestive.
General Thoracic Surgery Ellis et al
All cancers arose in the mucosa and were often ulcerat-
ed. Of the invasive tumors, 20% were well differentiated,
63% were moderately differentiated, and 5% were poorly
differentiated. Twelve percent were in situ squamous cell
carcinomas (invasive only into the lamina propria) and were
not graded for differentiation.
When depth of invasion was assessed, 55% were invasive
into the submucosa, 19% into the muscularis propria, and
14% invaded through the serosa into adjacent structures,
usually the liver. Remarkably, all but one of the cancers that
invaded through the serosa were either adenocarcinomas or
adenosquamous carcinomas. This is particularly important
in this model of BAA. Once again, 12% were only invasive
into the lamina propria.
Sixty-two percent of cancers were located at or near the
anastomosis (within one intermediate power field by light
microscopy—20×) and 43% were proximal, most of which
were squamous cancers. The total exceeds 100% because 2
cancers developed in 5 mice. 
Discussion
Decreased expression of the tumor suppressor gene p27 has
been identified in a number of human cancers, including can-
cers of the breast,14 colorectum,15 lung,16 and stomach,17
and has been associated with an aggressive behavior and a
poor prognosis. Our group was the first to identify a similar
phenomenon in resected BAA.5 Subsequently, others have
reported similar findings in cases of BAA18 and squamous
cell cancers of the esophagus.19 We have also shown that in
the colon,15 lung,16 and prostate (unpublished data, M.L.),
the reduced expression of the tumor suppressor gene p27
is the result of increased proteasome-mediated degradation.
Recently, the availability of p27 KO mice has permitted
animal research regarding the role of p27 in the develop-
ment of malignant diseases. Nakayama and associates20
showed that p27 KO mice exhibited only hyperplasia result-
ing in increased body size, multiple organ dysplasia, and
pituitary tumors, which was similar to the findings of Fero
and associates.11 However, when Fero and associates21
challenged both p27 KO and p27 heterozygous mice with
irradiation and a chemical carcinogen, tumors developed in
multiple tissues, although the mortality rate was higher in
the KO mice than in heterozygous mice.
The results we are reporting are similar in some respects
to those of Fero and associates.21 The importance of a car-
cinogen is clear from our studies, as evidenced by the high
cancer rate in group III mice. In another group of p27 KO
mice (not reported on here) that had esophagojejunostomy
without MBN, the cancer rate was only 29.2%, and the can-
cers were not adenocarcinomas. In a previous study of
ours,10 the importance of gastroduodenal reflux in addition
to the use of a carcinogen in the development of a BE and
BAA was clearly evident. BE rarely developed in wild type
Figure 3. Postmortem specimen of a p27 KO mouse after esophago-
jejunostomy and administration of a carcinogen. Two tumors are
visible (arrows). The distal tumor was an adenocarcinoma, and
the more proximal tumor was a squamous cell cancer.
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mice given only a carcinogen, and adenocarcinoma devel-
oped in none of them.
In contrast to the results reported by Fero and associates,21
no deaths occurred among our mice, but they were killed only
4 to 5 months after treatment, whereas those of Fero and asso-
ciates21 were followed up much longer. In addition, no
tumors developed elsewhere in the body in our mice, proba-
bly as a result of the fact that the carcinogen (MBN) that we
used has a predilection for inducing esophageal cancer. In
contrast to their study, we did not find a significantly higher
cancer rate in the heterozygous mice (group II), although this
may be due to the limited sample size.
The high cancer rate in p27 KO mice that underwent
esophagojejunostomy and administration of MBN (group III)
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 4 813
Figure 4. Hematoxylin and eosin stains of representative pathologic entities in p27 knockout mice. A,
Metaplastic Barrett epithelium present within esophageal squamous mucosa. B, Invasive squamous cell carci-
noma. C, Invasive adenocarcinoma. D, Invasive adenosquamous carcinoma. (Original magnification ×400.)
TABLE 1. Histopathologic findings
Finding Group I (n = 50) Group II (n = 45) Group III (n = 50) P value, groups I and II vs group III
Barrett esophagus 7 (14%) 4 (8.8%) 13 (26%) .035
Cancer 30 (60.0%) 31 (68.9%) 43 (86%) .006
Squamous cell 15 20 31*
Adenosquamous 12 6 7*
Adenocarcinoma 3 (10%)† 5 (16.1%)† 10* (23.3%)† NS
Group I, Esophagojejunostomy + carcinogen, p27 wild type; group II, esophagojejunostomy + carcinogen, p27 heterozygous; group III, esophagojejunos-
tomy + carcinogen, p27 KO; KO, knockout; n, number of mice; NS, not significant.
*The sum of these numbers is greater than 43 because 5 mice had 2 cancers (see text).
†Percent of total cancers.
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was highly significant (P = .006) when compared with the
cancer rate in mice in groups I and II. The percentage of can-
cers that were adenocarcinomas was higher in this group
(23.3%) and, although not significantly so, certainly exhibit-
ed a trend in that direction. Because it is generally accepted
that adenocarcinomas of the esophagus in human beings are
BE related, the rate of adenocarcinomas in group III mice
might have been even higher had these mice been killed after
a longer postoperative interval, particularly in view of the
higher rate of BE in mice of this group. Why the rate of BE
was highest among mice in group III is not clear, but it is pos-
sible that p27 may be involved in some fashion with epithe-
lial protection.22 The strict criteria we used in the definition of
BE, namely metaplastic epithelium bounded proximally and
distally by squamous epithelium, might have underestimated
somewhat its prevalence in the 3 arms of this study.
In conclusion, the experimental production of gastroduo-
denal-esophageal reflux in p27 KO mice treated with MBN
results in a high rate of BE and of cancer. Interestingly, the
rate of adenocarcinomas in this group was higher than that of
adenocarcinomas in p27 wild type and p27 heterozygous
mice, although the difference was not quite statistically sig-
nificant, probably because of the limited sample size. All the
same, some of the mice in group III had pathologic changes
similar in some respects to the disease that occurs in some
human beings. This model, therefore, may be useful in
developing methods to inhibit malignant transformation of
BE to BAA. The high rate of squamous cell cancers suggests
that this model could also be valuable in studying this form
of esophageal cancer. However, the addition of experimental
gastroduodenal-esophageal reflux to administration of car-
cinogen would be unnecessary since in an earlier study of
ours,10 11 of 15 (73%) cancers developing in wild type mice
treated only with a carcinogen were squamous cell cancers
of the esophagus, and none was adenocarcinoma.
We thank Gerald J. Heatley, MS, for statistical analysis of the
data, and Kosha Thakore for technical assistance.
References
1. Powell J, McConkey CC. The rising trend in oesophageal adenocarci-
noma and gastric cardia. Eur J Cancer Prev. 1992;1:265-9.
2. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of
esophageal adenocarcinoma: an update. JAMA. 1993;270:1320.
3. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the inci-
dence of esophageal and gastric carcinoma in the United States.
Cancer. 1998;83:2049-53.
4. Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of
the esophagogastric junction and Barrett’s esophagus. Gastroenterology.
1995;109:1541-6.
5. Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG,
et al. Loss or altered subcellular localization of p27 in Barrett’s asso-
ciated adenocarcinoma. Cancer Res. 1998;58:1730-5.
6. Slingerland J, Pagano M. Regulation of the Cdk inhibitor p27 and its
deregulation in cancer. J Cell Physiol. 2000;183:10-7.
7. Pera M, Cardesa A, Bombi JA, Ernst H, Pera C, Mohr U. Influence of
esophagojejunostomy on the induction of adenocarcinoma of the dis-
tal esophagus in Sprague-Dawley rats by subcutaneous injection of
2,6-dimethylnitrosomorpholine. Cancer Res. 1989;49:6803-8.
8. Attwood SE, Smyrk TC, DeMeester TR, Mirvish SS, Stein HJ, Hinder
RA. Duodenoesophageal reflux and the development of esophageal
adenocarcinoma in rats. Surgery. 1992;111:503-10.
9. Arbeit JM, Hirose R. Murine mentors: transgenic and knockout mod-
els of surgical disease. Ann Surg. 1999;229:21-40.
10. Xu X, LoCicero J III, Kulke MH, Loda M, Ellis FH Jr. Barrett’s esoph-
agus and associated adenocarcinoma in a mouse surgical model. J
Surg Res. 2000;88:120-4.
11. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A
syndrome of multiorgan hyperplasia with features of gigantism,
tumorigenesis, and female sterility in p27Kip1-deficient mice. Cell.
1996;85:733-44.
12. Levrat M, Lambert R, Kirshbaum G. Esophagitis produced by reflux
of duodenal contents in rats. Am J Dig Dis. 1962;7:564-72.
13. Barch DH, Iannaccone PM. Role of zinc deficiency in carcinogenesis.
Adv Exp Med Biol. 1986;206:517-27.
14. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo
EJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E,
alone and in combination, correlate with survival in young breast can-
cer patients. Nat Med. 1997;3:222-5.
15. Loda M, Cucor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al.
Increased proteasome-dependent degradation of the cyclin-dependent
kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med.
1997;3:231-4.
16. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG,
et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in
non-small cell lung cancer. Cancer Res. 1997;57:3381-5.
17. Han S, Kim HY, Park K, Lee MS, Kim HJ, Kim YD. Expression of
p27Kip1 and cyclin D1 proteins is inversely correlated and is associ-
ated with poor clinical outcome in human gastric cancer. J Surg Oncol.
1999;71:147-54.
18. Soldes OS, Kuick RD, Thompson IA 2nd, Hughes SJ, Orringer MB,
Iannettoni MD, et al. Differential expression of Hsp27 in normal
oesophagus, Barrett’s metaplasia and oesophageal adenocarcinomas.
Br J Cancer. 1999;79:595-603.
19. Okashi J, Sasano H, Yamaki H, Shigawa S, Shineha R, Akaishi T, et
al. Cell cycle inhibitor p27 in esophageal squamous cell carcinoma.
Anticancer Res. 1999;19:1843-8.
20. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N,
et al. Mice lacking p27(Kip1) display increased body size, multiple
organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell.
1996;85:707-20.
21. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine
gene p27Kip1 is haplo-insufficient for tumour suppression. Nature.
1998;396:177-80.
22. Quaroni A, Tian JQ, Seth P, Ap Rhys C. p27 (Kip1) is an inducer of
intestinal epithelial cell differentiation. Am J Physiol Cell Physiol.
2000;279:C1045-57.
